sotagliflozin sotagliflozin sotagliflozin, sold under the brand name zynquista, is a drug approved in the european union for people with type 1 diabetes. sotagliflozinclinical datatrade nameszynquistaroutes ofadministrationby mouthatc codea10bk06 (who) legal statuslegal status eu: rx-only identifierscas number1018899-04-1pubchem cid24831714drugbank12713chemspider27289071unii6b4zbs263ykeggd10669comptox dashboard (epa)dtxsid20144314 echa infocard100.231.837 chemical and physical dataformulac21h25clo5smolar mass424.94 g·mol−13d model (jsmol)interactive image smiles ccoc1=cc=c(c=c1)cc2=c(c=cc(=c2)3((((o3)sc)o)o)o)cl inchi inchi=1s/c21h25clo5s/c1-3-26-15-7-4-12(5-8-15)10-14-11-13(6-9-16(14)22)20-18(24)17(23)19(25)21(27-20)28-2/h4-9,11,17-21,23-25h,3,10h2,1-2h3/t17-,18-,19+,20+,21-/m1/s1key:qkdrxgfqvgoqks-crssmbpesa-n the most common side effect is genital infection in women. other common side effects include diabetic ketoacidosis, diarrhoea and genital infection in men. the us food and drug administration (fda) refused its approval for use in combination with insulin for the treatment of type 1 diabetes. it is developed by lexicon pharmaceuticals. sotagliflozin is a combination sodium/glucose cotransporter 1 and 2 (sglt1/2) inhibitor and is in the class of drugs known as gliflozins.